CABA — Cabaletta Bio Cashflow Statement
0.000.00%
- $68.00m
- -$86.74m
Annual cashflow statement for Cabaletta Bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -33.3 | -46.3 | -53 | -67.7 | -116 |
Depreciation | |||||
Non-Cash Items | 4.51 | 5.87 | 9.72 | 12.6 | 21.2 |
Other Non-Cash Items | |||||
Changes in Working Capital | 1.71 | 5.58 | -4.3 | 0.101 | 1.61 |
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Cash from Operating Activities | -26.8 | -34.1 | -46.4 | -53.5 | -88.2 |
Capital Expenditures | -0.635 | -1.17 | -2.45 | -0.687 | -2.21 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | -7.35 | 7.17 | -24.8 | -21.8 | 49.5 |
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | -7.98 | 6 | -27.2 | -22.5 | 47.3 |
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | -0.024 | 48.9 | 33 | 188 | 11.7 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -34.8 | 20.8 | -40.6 | 112 | -29.3 |